Lisuride in parkinsonism

Ann Neurol. 1981 Jan;9(1):48-52. doi: 10.1002/ana.410090109.

Abstract

Lisuride is a soluble ergolene derivative with endocrine effects similar to but more potent than those of bromocriptine. In nine subjects with idiopathic, postencephalitic, or drug-induced parkinsonism, lisuride at a dosage of 0.05 to 0.15 mg intravenously caused an immediate improvement in tremor, rigidity, akinesia, and postural deformity, but also caused chorea and orofacial dyskinesia. Improvement lasted 2 to 3 hours. Lisuride had little or no effect in a single patient with progressively supranuclear palsy. Oral lisuride therapy, 0.8 to 4.8 mg daily, had similar effects but occasionally caused reduced awareness and hallucinations.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Aged
  • Benzimidazoles / administration & dosage
  • Chorea / chemically induced
  • Domperidone
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Dyskinesia, Drug-Induced / etiology
  • Ergolines / therapeutic use*
  • Female
  • Growth Hormone / blood
  • Humans
  • Injections, Intravenous
  • Lisuride / administration & dosage
  • Lisuride / therapeutic use*
  • Male
  • Middle Aged
  • Paralysis / drug therapy
  • Parkinson Disease / drug therapy*
  • Parkinson Disease, Postencephalitic / drug therapy
  • Parkinson Disease, Secondary / chemically induced
  • Piperidines / administration & dosage
  • Prolactin / blood

Substances

  • Benzimidazoles
  • Ergolines
  • Piperidines
  • Domperidone
  • Prolactin
  • Growth Hormone
  • Lisuride